Please login to the form below

Not currently logged in
Email:
Password:

RG3039

This page shows the latest RG3039 news and features for those working in and with pharma, biotech and healthcare.

Pfizer acquires spinal muscular atrophy research programme

Pfizer acquires spinal muscular atrophy research programme

Gains rights to drug candidate RG3039 in deal with Repligen that could be worth up to $70m. ... $5m. The main candidate involved in the programme is RG3039, which will undergo phase I trials carried out by Repligen in the first quarter of 2013.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2013 Pharma deals during January 2013

    This programme includes RG3039, a small molecule drug candidate in clinical development, as well as backup compounds and enabling technologies. ... Acquisition. Antibody manufacturer. 70. Repligen / Pfizer. Licence. RG3039 orphan for spinal muscular

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....